This article has Open Peer Review reports available.
Induction of cytotoxic T lymphocytes primed with Tumor RNA-loaded Dendritic Cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design
© Gholamin et al; licensee BioMed Central Ltd. 2010
Received: 16 November 2009
Accepted: 7 June 2010
Published: 7 June 2010
Dendritic Cells (DC) are potent antigen presenting cells with the ability to prime naïve T cells and convert them to cytotoxic T-lymphocytes (CTL). We evaluated the capability of autologous DCs transfected with total tumor and normal RNA to induce cytotoxic CTL as the preliminary step to design a DC-based vaccine in the esophageal squamous cell carcinoma (ESCC).
Monocytes-derived DCs were electroporated with either total tumor RNA or normal RNA. T cells were then primed with tumor RNA transfected DCs and lytic effects of the generated CTL were measured with Cytotoxicity assay and IFN-γ Release Elispot assay.
Cytotoxicity was induced against DCs loaded with tumoral RNA (%24.8 ± 5.2 SEM) while in normal RNA-loaded DCs, it was minimal (%6.1 ± 2.4 SEM) and significantly lower (p < 0.05). INF-γ secretion was more than 2-folds higher in tumoral RNA-loaded DCs when compared with normal RNA-loaded DCs (p < 0.05).
Electroporating DCs with tumor RNA generated tumor antigen presenting cells which in turn enhanced cytotoxic effects of the T cells against ESCC. This may be a useful autologous ex vivo screening tool for confirming the lytic effects of primed T cells on tumors and evaluate probable further adverse effects on noncancerous tissues. These data provide crucial preliminary information to establish a total tumor RNA-pulsed DC vaccine therapy of ESCC.
Gastrointestinal cancers are the most frequent cancer malignancy in the Iranian population with substantial numbers of the patients reported from northern and northeastern Iran. Esophageal squamous cell carcinoma (ESCC) is the fifth leading cause of cancer-related deaths in Iran . Most cases of ESCC in Iran as well as many other countries are diagnosed in advanced stages . Surgical treatment and adjuvant therapeutic modalities such as chemo- and radiotherapy have only a minimal effect on patient outcome and the overall 5-years survival rate is less than 25%.
Immune system plays an important role in counterbalancing against the malignant transformation and escape from immunologic surveillance and the subsequent immune privilege of tumor may account for the development of some cancers including ESCC . On the other hand, the suggested correlation between the infiltration of T cells in the tumor environment and good prognosis demonstrated in several tumors represents a naturally occurring adaptive immunity in cancer patients . Immunotherapeutic strategies are designed and optimized based on a better understanding of different escape mechanisms. Nonfunctional presentation of tumoral antigen and further suppression of an effective immune response is one of the most important mechanisms of immune evasion which has been targeted in designing a number of immunotherapeutic modalities.
Dendritic cells (DC) are professional antigen capturing cells which initiate primary and further secondary immune responses in vivo. Their unique functions are mediated by priming the naïve T cells and cross-presenting various antigens. Maturation is an important characteristic of DCs during which immature DCs, as phagocytic cells capture foreign antigens at the site of injury and become mature cells along the process of presenting the antigen peptides on MHC class I and II molecules . Mature DCs will then migrate to local lymph nodes to present antigens to naïve T cells and convert them into effector cells of the immune system against non-self antigens . Taking advantage of this in vivo model, incubation of DCs with tumor specific molecules such as proteins, peptides, or lysates, or transfecting them with nucleic acids encoding tumor specific antigens is the basic concept of designing DC-based cancer immunotherapy .
Electroporation is assumed as the most efficient method for delivering the genetic materials into the cells . In this procedure, a mixture of cells and mRNA are pulsed at a specific voltage for a short period of time. Resulting is a small pore on the cell membrane which makes it possible to pass mRNA into the cells . Gilboa et al pulsed DCs with tumor antigen-encoding mRNA and reported an effective therapeutic tumor vaccination when it was administered in a murine model for the first time . Although various studies have tried to find a specific tumor marker for ESCC, an appropriate marker has yet to be found for the purpose of immunotherapy. Therefore, in this study we loaded DCs with total mRNA to transfer the genetic material. T cell response was evaluated after priming with DCs transfected with tumoral mRNA from ESCC patients as a preliminary step to establish a DC vaccine for ESCC.
Sample collection and RNA isolation
Four histologically-approved ESCC patients were included in the study prior to any therapeutic interventions. After obtaining informed consents, approximately 50 ml of blood was collected in heparinized vials for extraction of peripheral blood mononuclear cells (PBMCs). Tumoral tissue was microdissected and stored in RNAlater (Qiagen, Hilden, Germany) until RNA extraction. Corresponding normal tissue from the affected esophagus was obtained using the same protocol. Total RNA was extracted by RNeasy kit (Qiagen, Hilden, Germany). RNA integrity was confirmed by electrophoresis on agarose gel and the concentration and purity was checked by spectrophotometry at 260 nm and 280 nm. The study was approved by the Research Ethics Committee of Mashhad University of Medical Sciences.
Generation of dendritic cells
Peripheral blood mononuclear cells were obtained from 50 ml of heparinized whole blood via Ficoll-Hypaque (Biosera Inc., East Sussex, United Kingdom). The generation of DCs was performed on CD14+ cells isolated by the EasySep® Human Monocyte Enrichment Kit without CD16 Depletion (Stemcell Technologies, Vancouver, Canada). Cells were seeded for 5 days into six-well plates in RPMI1640 supplemented by 10% heat-inactivated FBS, penicillin (100 U/ml), streptomycin (100 mg/ml), L-glutamine (2 mM), sodium pyruvate, 2ME (2-Mercaptoethanol) (50 mM), human Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF) 800 IU (R&D System Inc., Minneapolis, MN, USA) and IL-4 500 IU (R&D, USA). GM-CSF and IL-4 were again added on the third day. The production of immature DCs was detected by specific CD markers using BD FACSCalibur (BD Biosciences, CA, USA). Cells were electroporated with tumor or normal mRNA on the sixth day, followed by the maturation of the cultured DCs with TNF-α (50 ng/ml) 4 hours after electroporation. Electroporated mature cells were analyzed for transfection using flow cytometry after 24-48 hours.
FACS (Fluorescence-Activated Cell Sorting) analysis of immature DC
Immunofluorescence staining of monocyte-derived DC with differentiation and activation markers was performed for the phenotypic analysis of DCs. Anti-HLA DR, CD1a, CD80, CD86, CD83, FITC-conjugated (Fluorescein Isothiocyanate), and CD14 PE-conjugated (Phycoerytherin) mouse monoclonal antibodies (IQ Company, Netherlands) were used for the FACS analysis. Appropriate mouse PE/FITC isotype was used as negative control.
Prior to electroporation on day 6, immature DCs were washed twice with the Opti-MEM medium (GibcoBRL, Eggenstein, Germany) and resuspended to a final concentration of 10 × 106 cells/ml. Subsequently, 100 μl of the cell suspension was initially mixed with 2.5 μg of Enhanced Green Fluorescent Protein (EGFP) mRNA per 106 cells to confirm the transfection procedure. After confirming the transfection procedure, DCs were transfected with 1.5 μg of tumoral mRNA per 106 cells or 1.5 μg of corresponding normal mRNA per 106 cells. Transfection was performed using a BTX ECM830 square-wave electroporator with a single 500 V/300 μs pulse (Genetronics, San Diego, CA, USA).
After pulsing, all the cells were gently and immediately removed from the cuvette and poured into 6 well plates, in which the containing media was pre-warmed at 37°C. For negative control of electroporation reaction, mock DCs were electroporated under the same conditions but without the addition of mRNA.
Generation of in vitro-transcribed EGFP mRNA
In order to confirm the gene transfer efficiency by the electroporation method, in vitro-transcribed (IVT) EGFP mRNA was applied as a reporter gene. pGEM4Z/GFP/A64 plasmid containing the poly(A) template (kindly provided by Dr. E. Gilboa, University of Miami, FA, USA) was utilized for in vitro transcription of EGFP mRNA. This plasmid was transformed into E. coli Top10F and purified with a QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). Following vector linearization by the restriction enzyme SpeI and purification, DNA template was used for in vitro transcription under the control of a T7 promoter with the T7 RNA polymerase. In vitro capped RNA was synthesized by the Message MACHINE kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The concentration and purity of amplified EGFP RNA was evaluated by spectrometric analysis of absorbance at 260 (A260) and 280 nm (A280) and by 2% agarose/EtBr gel electrophoresis. The DCs electroporated with IVT EGFP mRNA were directly checked by fluorescent microscope and underwent FACS analysis to evaluate the efficiency of transfection which is represented by the percentage of transfected cells in a live population. The introduction efficacy is calculated by multiplying the percentage of viable cells by the transfection efficiency.
Induction of tumor-specific CTL using DCs transfected with tumor RNA
For CTL generation, the T-cell-enriched non-adherent fraction of PBMCs was obtained after the DC plastic adherence step was performed. T-Cells were suspended in RPMI1640 with 10% fetal calf serum, 25 mM Hepes, L-glutamine, and antibiotics. Of the T-cell-enriched PBMCs, 2 × 106 cells were combined with 2 × 105 transfected matured DCs and 10 ng/ml IL-7 in a total volume of 2 ml, in the wells of a 24-well tissue culture plate and cultured at 37°C in 5% CO2 for 8 days. IL-2 was added to the culture in the third day at a concentration of 20 IU/ml. After 8 days, the effectors were harvested, washed, counted, and re-stimulated with newly transfected DCs. Adding IL-2 and IL-7 with the same concentrations to the culture, the cells were incubated for another 8 days to successfully induce tumor specific CTL.
To determine cytotoxicity, the calcein-AM cytotoxicity assay was performed. Prior to the cytotoxicity assay, target cells were re-suspended in RPMI-1640 complete medium at a final concentration of 106 cells/ml and incubated with 10 μM calcein-AM (Invitrogen inc., Grand Island, NY, USA) for 30 min at 37°C with occasional shaking, treated with 50 μg/ml of mitomycin C for 30 min, and washed three times with RPMI-1640 medium. Effectors and calcein-labeled targets were co-cultured in U bottom 96-well plates in triplicates for 4 h at 37°C in a total volume of 200 μl with various effector:target (E:T) ratios i.e. 1:1, 3:1 and 9:1. Supernatant samples were measured using a fluorescence spectrophotometer (FP-6200, Jasco, Japan; exciting filter: 485 ± 9 nm; band-pass filter: 530 ± 9 nm). Data were expressed as arbitrary fluorescent units (AFU). Percent cytotoxicity of the assay was calculated by the following formula: [(test release - spontaneous release)/(maximum release - spontaneous release)] × 100. The maximum release and spontaneous release represent calcein release from the targets in the medium, with and without 2% Triton X-100, respectively.
IFN-γ release Elispot assay
The IFN-γ release Elispot assay was performed by an Elispot kit (U-CyTech biosciences, Utrecht, Netherlands) according to the manufacturer's instructions. Briefly, 96-well plates with transparent membranes were coated with 50 μL primary anti-IFN-γ antibodies and incubated at 4°C for at least 18 h. After washing the plates with the washing buffer five times, individual wells were blocked for nonspecific binding with 200 μL RPMI containing 10% FBS at 37°C for 1 h. After removal of the blocking solution, 4 × 104 responder T cells and 2 × 103 mitomycin-treated stimulator cells were added in a total volume of 200 μL RPMI medium containing 10% FBS. Stimulator cells included DCs transfected with tumoral or normal mRNA and also mock DCs. Each experimental condition was plated in triplicates and incubated at 37°C in 5% CO2 for 24 h. Cultures were removed and the plates were washed ten times with the washing buffer. One hundred microliters of properly diluted biotinylated detection anti-IFN-γ antibody was added to each well and incubated overnight at 4°C. The plates were washed with the washing buffer five times and 50 μl of labeled anti-biotin antibody was added to each well and incubated at 37°C in the dark for 1 h. Washing was repeated five times and activator solutions were added to detect the sites of cytokine secretion by revealing the black spots. The plates were developed in the dark for 30 min. The reactions were stopped by rinsing with tap water and spots were imaged and counted at the final step.
Results were expressed as the mean ± SD. Statistical analysis of cytotoxicity and Elispot tests were conducted by unpaired Student's t-test and paired Student t-test using SPSS software (version 16). A value of p < 0.05 was considered statistically significant.
Clinicopathological characteristics of patients.
FACS analysis of monocyte-derived DCs
Phenotypic characterization of immature and mature DCs by flow cytometry.
% Immature DC
% Mature DC
Electroporation efficacy represented by GFP mRNA transfection into DC
Due to its asymptomatic nature, ESCC is often diagnosed in its advanced stages where the common therapeutic modalities are not very effective and the 5-year survival rates do not exceed 25%. Therefore, approaches to novel therapeutic modalities seem to be an essential step to improve the survival rate of ESCC patients. We have previously shown that immune escape is a frequent event in the Iranian ESCC patients. This suggests that immunotherapy can be a potentially effective tool to reverse malignant transformation of cells by enhancing immune responses .
Dendritic cells have a unique capacity to capture, process, and present antigens that establish primary and secondary immune responses [13–15]. Taking advantage of their capabilities, DC transfection with nucleic acids encoding tumor specific antigens leads to processing and presenting the antigens and consequently, activating tumor-specific CTLs . Considering this fact, DCs are proposed as an effective target for vaccinating cancer patients against tumor antigens and promoting an immune response against tumors [16, 17]. It has been shown that RNA transfection of DCs offers numerous advantages over transferring other molecules [18, 19]. mRNA delivery system is an efficient method compared to the viral vectors as they do not pose the problems associated with viral vectors . DCs can be introduced by total tumoral mRNA and the identification of tumor associated antigens (TAAs) or HLA-typing is not obligatory  especially in cancers such as ESCC in which wide variety of genotypic and phenotypic features lead to lack of specific tumor markers in different populations . Loading total tumoral mRNA decreases the probability of immune escape via polyclonal activation of T cells against varied range of tumor-specific antigens and minimizes the consequences of antigen loss in mutant tumor cell clones. As RNA has a short half-life and lacks the ability to integrate into genome, many problems with viral vectors are not encountered . With regards to gene expression, mRNA transfection is more efficient than DNA transfection as it bypasses the transcriptional regulation processes and has easy access to the cytoplasmic translation machinery when transferred into the cells . Both CD4+ and CD8+ T lymphocytes will be activated by tumoral RNA transfer into DCs . Electroporation has proved to be a more efficient method of gene transfer than many other techniques . Thus, the electroporation method was utilized in order to achieve efficient total mRNA transfer into DCs as the preliminary step of a DC vaccine design for ESCC. In the present study, the results of mRNA transfer efficiency with electroporation (approximately 80%) were comparable to the previous reports of highly efficient transfer applying the same method [5, 24].
Clinical trials using antigen-loaded DCs have been published in various types of cancer including myeloid leukemia , medullary thyroid carcinoma , metastatic melanoma , pancreas cancer , colorectal cancer  and other malignancies. To our knowledge, only Millano et al have reported DC therapy on two ESCC patients in addition to five esophageal adenocarcinomas with some technical variations compared to our study . Our results show that primed T lymphocytes have obtained the capability to lyse the tumor RNA-loaded DCs. The percentage of lysis varies between 17.5 and 35 in the E:T ratio of 9. A serious limitation of this study was restricted amount of DCs since we were not able to perform leukophoresis in our patients. Many studies have performed the cytotoxicity assay in higher ratios [31, 32]. However, due to our restrictions in the available amount of DCs, we did not perform the assay in higher ratios and probably in higher E:T ratios, greater percentage of cytotoxicity might have been observed. Cytotoxicity percentage in the mock DCs, as in controls, was negligible.
Transfecting DCs with total tumor RNA brings up a major concern of a consequent adverse effect through breaking tolerance towards self antigens and thus destructing effects on normal tissues as well. In the present study, cytotoxicity against normal RNA-loaded DCs was minor while lytic activity of primed T cells induced by DCs loaded with tumor RNA was significantly higher than normal RNA-loaded DCs in each patient and when comparing the average of both groups by paired t-test. Millano et al have reported enhanced lytic response against some of the studied normal tissues in esophageal adenocarcinoma suggesting the possibility of adverse effects against normal tissues in esophageal cancer . Therefore, a preclinical ex vivo autologous assessment may be a wise step to include the beneficiary cases and predict the possibility of the adverse effects.
In summary, we demonstrated that electroporating DCs with tumor mRNA will enhance the cytotoxic effects of T cells against tumor in ESCC patients. Enhanced cytotoxicity induced by tumor RNA-loaded DCs is introduced as a useful autologous ex vivo screening tool for confirming the lytic effects of primed T cells on tumor and evaluates probable further adverse effects on noncancerous tissues. Enhancing cytotoxicity against tumoral cells is a crucial preliminary step to establish a total tumor RNA-pulsed DC vaccine therapy of ESCC.
We are very grateful to Dr. Eli Gilboa for generously providing us with the EGFP plasmid and his valuable consults. This study was supported by grants from Mashhad University of Medical Sciences, Iran National Science Foundation and Digestive Disease Research Center of Tehran University of Medical Sciences. The results described in this paper were part of a Ph.D. student dissertation.
- Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z: Cancer incidence and mortality in Iran. Ann Oncol. 2009, 20 (3): 556-563. 10.1093/annonc/mdn642.View ArticlePubMedGoogle Scholar
- Kamangar F, Malekzadeh R, Dawsey SM, Saidi F: Esophageal cancer in Northeastern Iran: a review. Arch Iran Med. 2007, 10 (1): 70-82.PubMedGoogle Scholar
- Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res. 1970, 13: 1-27.View ArticlePubMedGoogle Scholar
- Rajjoub S, Basha SR, Einhorn E, Cohen MC, Marvel DM, Sewell DA: Prognostic significance of tumor-infiltrating lymphocytes in oropharyngeal cancer. Ear Nose Throat J. 2007, 86 (8): 506-511.PubMedGoogle Scholar
- Landi A, Babiuk LA, van Drunen Littel-van den Hurk S: High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukoc Biol. 2007, 82 (4): 849-860. 10.1189/jlb.0906561.View ArticlePubMedGoogle Scholar
- Brossart P, Wirths S, Brugger W, Kanz L: Dendritic cells in cancer vaccines. Exp Hematol. 2001, 29 (11): 1247-1255. 10.1016/S0301-472X(01)00730-5.View ArticlePubMedGoogle Scholar
- Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005, 5 (4): 296-306. 10.1038/nri1592.View ArticlePubMedGoogle Scholar
- Van Bockstaele F, Pede V, Naessens E, Van Coppernolle S, Van Tendeloo V, Verhasselt B, Philippe J: Efficient gene transfer in CLL by mRNA electroporation. Leukemia. 2008, 22 (2): 323-329. 10.1038/sj.leu.2405007.View ArticlePubMedGoogle Scholar
- Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G: A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol. 2003, 58 (5): 578-586. 10.1046/j.1365-3083.2003.01333.x.View ArticlePubMedGoogle Scholar
- Boczkowski D, Nair SK, Snyder D, Gilboa E: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996, 184 (2): 465-472. 10.1084/jem.184.2.465.View ArticlePubMedGoogle Scholar
- Minami K, Yamaguchi Y, Ohshita A, Kawabuchi Y, Ohta K, Hihara J, Toge T: Generation of antigen-presenting cells using cultured dendritic cells and amplified autologous tumor mRNA. Oncology. 2005, 69 (5): 399-407. 10.1159/000089994.View ArticlePubMedGoogle Scholar
- Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, Sotoudeh M, Rajabi-Mashhadi MT, Forghani MN, Farrokhi F, Abbaszadegan MR: Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg. 2009, 33 (7): 1439-1445. 10.1007/s00268-009-0070-y.View ArticlePubMedGoogle Scholar
- Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G: Dendritic cells as vectors for therapy. Cell. 2001, 106 (3): 271-274. 10.1016/S0092-8674(01)00448-2.View ArticlePubMedGoogle Scholar
- Van Tendeloo VF, Ponsaerts P, Berneman ZN: mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther. 2007, 9 (5): 423-431.PubMedGoogle Scholar
- Kyte JA, Gaudernack G: Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2006, 55 (11): 1432-1442. 10.1007/s00262-006-0161-7.View ArticlePubMedGoogle Scholar
- Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, et al: Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006, 55 (7): 819-829. 10.1007/s00262-005-0078-6.View ArticlePubMedGoogle Scholar
- Hersey P, Halliday GM, Farrelly ML, DeSilva C, Lett M, Menzies SW: Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother. 2008, 57 (7): 1039-1051. 10.1007/s00262-007-0435-8.View ArticlePubMedGoogle Scholar
- Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000, 60 (4): 1028-1034.PubMedGoogle Scholar
- Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E: Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 1998, 16 (4): 364-369. 10.1038/nbt0498-364.View ArticlePubMedGoogle Scholar
- Dietz AB, Vuk-Pavlovic S: High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood. 1998, 91 (2): 392-398.PubMedGoogle Scholar
- Ohshita A, Yamaguchi Y, Minami K, Okita R, Toge T: Generation of tumor-reactive effector lymphocytes using tumor RNA-introduced dendritic cells in gastric cancer patients. Int J Oncol. 2006, 28 (5): 1163-1171.PubMedGoogle Scholar
- Saeboe-Larssen S, Fossberg E, Gaudernack G: mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods. 2002, 259 (1-2): 191-203. 10.1016/S0022-1759(01)00506-3.View ArticlePubMedGoogle Scholar
- Ponsaerts P, Van Tendeloo VF, Berneman ZN: Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol. 2003, 134 (3): 378-384. 10.1046/j.1365-2249.2003.02286.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C, Van Bockstaele DR, Berneman ZN: Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001, 98 (1): 49-56. 10.1182/blood.V98.1.49.View ArticlePubMedGoogle Scholar
- Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF: Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009, 1-16.Google Scholar
- Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R, Brostjan C, Riss S, et al: Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep. 2009, 21 (6): 1585-1592. 10.3892/or_00000391.View ArticlePubMedGoogle Scholar
- Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, et al: Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006, 13 (10): 905-918. 10.1038/sj.cgt.7700961.View ArticlePubMedGoogle Scholar
- Kalady MF, Onaitis MW, Emani S, Abdul-Wahab Z, Pruitt SK, Tyler DS: Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J Gastrointest Surg. 2004, 8 (2): 175-181. 10.1016/j.gassur.2003.11.003.View ArticlePubMedGoogle Scholar
- Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, Rosenberg J: Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep. 2008, 20 (6): 1305-1311.PubMedGoogle Scholar
- Milano F, Rygiel AM, Buttar N, Bergman JJ, Sondermeijer C, van Baal JW, ten Brinke A, Kapsenberg M, van Ham SM, Peppelenbosch MP, et al: An ex vivo readout for evaluation of dendritic cell-induced autologous cytotoxic T lymphocyte responses against esophageal cancer. Cancer Immunol Immunother. 2007, 56 (12): 1967-1977. 10.1007/s00262-007-0341-0.View ArticlePubMedGoogle Scholar
- Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, et al: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol. 2001, 166 (5): 2953-2960.View ArticlePubMedGoogle Scholar
- Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 2001, 61 (8): 3388-3393.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/10/261/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.